Sign in: Staff/Students
Two new therapies are to be studied in patients as part of the ground-breaking AGILE clinical trial platform, with the hope of finding treatments for people with COVID-19.
The trial is being funded by over £3m of investment from GlaxoSmithKline and Vir Biotechnology who have joined forces with researchers from the Universities of Liverpool and Southampton who are leading early phase trials to test new treatments for COVID-19.
The two monoclonal antibody therapies, VIR-7831 and VIR-7832, will be given to patients who have tested positive for COVID-19 and have mild or moderate symptoms. Pre-clinical studies of these antibody therapies have already demonstrated promising results in combatting coronavirus infections. While VIR-7831 is currently being evaluated in two Phase 3 clinical trials, the AGILE study marks the first in-human trial of VIR-7832.
This is the second therapeutic trial within the UK government supported AGILE drug testing platform. This ground-breaking collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, NIHR Liverpool and Broadgreen Clinical Research Facility based at the Royal Liverpool University Hospital, the NIHR Southampton Clinical Trials Unit at the University of Southampton, Lancaster University and the UK Clinical Research Facility Network aims to rapidly identify therapies that have the potential to be used to treat COVID-19 patients and bring them into early phase clinical trials.
Professor Saye Khoo from University of Liverpool is Chief Investigator for the trial. He said: “A number of monoclonal antibodies are being studied for treatment of COVID-19, each different in its own way. The potential for VIR-7832 to not only bind SARS CoV-2, but also to stimulate the immune system is a unique feature, and we are very keen to study whether this confers any additional treatment benefit.”
Dr Richard Fitzgerald, Director of the NIHR Liverpool and Broadgreen Clinical Research Facility, said: “We are really pleased to be able to take this trial forward in our Clinical Research Facility, an MRHA accredited unit with a vast experience of conducting first-in-human trials, and we are looking forward to expanding this trial into other CRF sites across the UK in the coming months with support from the MRC.”
Professor Gareth Griffiths, Director of the NIHR Southampton Clinical Trials Unit, said: “We are incredibly excited to be adding these two new drugs into the AGILE trial platform. The COVID-19 vaccination programme has given everyone hope that we will bring this virus under control, but it will take time. We therefore need to continue to find safe and effective treatments for people who will unfortunately get COVID-19 and the AGILE platform is a major part of this.”
The AGILE trial platform was launched in July 2020, and the first treatment in the drug testing platform entered into patient trials in Liverpool in September.
All recent news
Obituary: Ian Jobes
Summer Term Events Programme (STEP) – My review of week four
Blog: How science and society came together for the Events Research Programme
REMINDER: Module registation closes on Monday 10 May
Significant progress in lithium-air battery development
Our paper on immune responses to COVID vaccine (mostly Pfizer) in 237 healthcare workers, 124 #SARSCoV2 naïve and 113 previously infected, from the PITCH consortium @pitchstudy is out as a pre-print today.
See if you can spot us in the new @NetflixUK series, The Irregulars! 📽️
Our @VictoriaGallery appears in it, as well as other locations across the city including St George’s Plateau, the Palm House in Sefton Park and Falkner Street in the Georgian Quarter.
Professor Michael Parkinson CBE, author of 1985's Liverpool on the Brink, and Liverpool Beyond the Brink in 2019, analyses the Caller Report, the Gov's Best Value inspection into Liverpool City Council